

Resolving code names to structures from the medicinal chemistry literature: Not as FAIR as it should be


Reshaping Discovery Together

Roxana-Maria Rujan ORCID 0000-0002-4335-3338

Data Science, Medicines Discovery Catapult,
Macclesfield, UK, SK10 4ZF https://md.catapult.org.uk/

#### Outline

- Example Compound Codenames (CN)
- CN in the wild
- Rogues' gallery
- Manual collation of CNs
- Automatic CN retrievals
- Curation of CN from J Med Chem
- FAIR-ness aspects
- Concluding remarks and plans



# CN from two years of J.Med.Chem

S1-6e UZH2 RPE65 TAS-116 TAK-981 MK-8262 SPR519 OI338 GC-14 MK-8153 FRM-024 LYS006 SLC-149 LU13 TAK-020 FGF401 CC-90001 BLU-945 LFS-829 FM26 TO-317 EC5026 UCB7362 S06-1011 CC-90005 NCS-382 ZW4864 CJ-2360 PF-562271 I-BET282E S11-1014 GAT211 K117 EX527 CX-4945 MRTX0902 FPFT-2216 GLPG2451 SHU-9119 MT-3995 MK-4688 S-217622 CHF-6366 BAY-6672 GDC-0276 PQQ GB1211 T-914 RP-6685 SPH3127 BPR1R024 LY3202626 BAY-8400 PRN1008 MG624 D24 SLL-627 ORG27569 VU6019650 CH7057288 MMV665917 MRS8054 JXL001 K-5a2 SK-575 NUC-1031 BAY-4931 BMS-986202 BMS-986313 CHDI-626 QCP01 ST-2001 SJ6986 SCO-267 LSN3318839 ACT-672125 BMS-820132 BCX7353 SY-5609 NEt-C343 CCF0058981 PF-06865571 ANAVEX2-73 AZD4831 TNIR7-1A 13b-K LEI-401 GNE-064 BMS-963272 GSK3640254 SUVN-D4010 RGD-SS-CA AS-1763 HP590 R)-AS-1 IACS-15414 SPH5030 3a-P1 Hu7691EST73502 AzoGW1929 SGC-STK17B-1 INE963 EST64454 ACH-000143 NCATS-SM1440 R)-AS-1 SAGE-718 TH257 CNP520 BRD0639 LYC-55716 TK-129 CC-90009 LT-850-166 PF-06455943 QNX-sLXms GSK3739936 NSC791985 AS-0141 PF-74 RB394 CM-444 PSMA-1092 GSK3494245 N-CTX-Ltg1a NTQ1062 BMS-986120 MRTX1133 UMB298 UCF501 CQ211 KSL-128114 BAY-1101042 S)-VU0637120 DC-PRC2in-01 PBI-4DNJ-1 QN523 V-0219 MP135 808-NM2 LY3154885 ARUK3001185 R)-STU104 QPX7831 BMS-986144 MRTX1719 WS-691 A17 BIIB091 AZD9833 JNJ-64264681 ACT-1004-1239 PF-06843195 QBW251 SR18292 XL-147 SZM679 GQ127 AZD0284 JNJ-63576253 Ga-bisNODAGA E197 PF 07050013 MSD-496486311 ABBV-3373 BGB-290 AG-270 K122 PF-07059013 MSD-496486311 MRIA9 VZMC013 ARD-2585 pF-06873600 NCATS-SM5637 ARN-21934 CRCM5484 GW4064 SHA-68 IPN60090 IDO443 SHA-68 IPN60090 JDQ443 ACT-660602 JNJ-54861911 GS-441524 I-BET567 AF27139 CK-274 AZD8154 MS-955176 SIAIS164018 DNDI-6148 GNE-0749 MAK683

R)-7 BT8009 EEDi-5273 BMS-985278 BAY1214784 POR620 I-BET432 KW 2523 AP1 KVD900 ICRF-193 INCB054828 BMS-986339 ANT3310 ITH15004 MLT-231 F3A BMS-986278 BAY1214784 PQR620 I-BET432 KK-052 ZN-c3 M2698 KT-531 LEO39652 AZD4573 IHMT-PI3KÎ AZD5305 MSC-4106 RRx-001 SMU-C80 DDO-2213 ARN19689 GLPG1972 D6808 CVN424 LP-922056 DC-BPi-07 GLPG1205 UCM-1306 A23 NB-360 BAY-091 IDR-1002 HSGN-218 SGC6870 S64315 BAY-069 SLL-1206 NIC-0102 BI-3406 PI-2620 TAM16
ZCM-I-1 KGOP01 CC-90011 CJ2-150 SW-101
XD2-149 MK-1454 heMAMP MK-0159 SW-101 WSJ-557 RP-6306 RLX-33 TNO155 P18UK-5099 TUG-891 B53 ID09

## CN in the wild : good and bad news

- Full codename-to-structure (CNn2s) with SAR in quality journals defines the leading edge of global drug discovery
- "XXX-12345" is predominant
- Many leads only have codeless locants from the papers (e.g., "compound 21")
- It would be good if authors performed specificity checks and homonym clashes (e.g., Google, PubMed, PubChem) – e.g., A17 compound
- Can get CN "daisy chains" via company mergers and acquisitions
- Companies re-badging "old chestnut" compounds with new CN

### CN in the wild : good and bad news

- Guide to Pharmacology, BindingDB and ChEMBL annotate many CN2s and submit to PubChem
- Curation is selective and lags by 2- 12 months
- In PubChem multiple CN + INN + USANs + trade names leads to "synonym spaghetti"
- Confounded by 45% of USANs being mixtures
- Same CN systems for biologicals as well as small-molecules
- Press release CN and majority of Phase I and II clinical trial compounds are still "blinded" (no CN2s)

## Rogues Gallery: confounding "Findability" in FAIR

- Overdoing the digits most promising molecule, 12126065, exhibited antiviral > 8 spurious matches in NCBI databases
- Confusing and search-challenging punctuation (R)-7 [(R)-AS-1] show

(R)-7 [(R)-AS-1] showed broad-spectrum antiseizure activity

• The great hyphen ambiguity > 3-fold permutation across data sources







Chinese teams using alphabetic locants that look like CN

Mechanistically, L24 exhibited significant in vivo antitumor effects



## Rogues Gallery: confounding "Findability" in FAIR

• Peptide challenges with toxins from a scorpion and a spider. Here, we described a cone snail toxin, N-CTX-Ltg1a, with a

• Zentalis Pharma – needs an internal registration system e.g. ZNPxxxxxx?

of compound **16** provided an unexpected improvement of Wee1 potency. Compound **16**, known as ZN-c3, showed excellent *in vivo* efficacy and is currently being evaluated in phase 2 clinical trials.

Shanghai Institute for Advanced Immunochemical Studies – shorten to SIAxxxxxx?

Discovery of a Brigatinib Degrader SIAIS164018 with

## MDC internal Codename project - a competitive intelligence initiative

- Journal of Medicinal Chemistry PubMed Abstracts were curated for the detection of new CNs potentially resolvable to lead molecules
- This harvests latest drug discovery outputs, including AI/ML designed compounds
- Resolved compounds can now be explored in silico by MDC informatics and sourced for in vitro experiments by MDC Discovery Sciences
- Our internal feed is months ahead of other sources
- From quality journals, manual curation of the latest CNs is possible


#### REGEX > automated CN mining

- Automated recognition of CNs from PubMed abstracts or any text
- Used 300 CNs as starting point but tune to include new ones
- Compiled False Positive (FP) blacklist including gene names and cell lines
- Used PubMed counts as a True Positive (TP) filter
- Short CNs still challenging for FPs




# Automated CN mining from key Journals

- ~ 19K PubMed CNs from 6 journals
- J.Med.Chem has most CNs
- Includes some false positives (FPs) but frequency is low
- Some CNs not in abstract
- Provisional portfolio mappings
  - PF- = 142
  - GSK = 136
  - AZD = 93



# Codename Pipeline



## Codename Pipeline – Codename Dashboard



#### Codename Dashboard

Introducing our Codename Dashboard: the ultimate solution for pharmaceutical compound identification. Uncover codenames, analyze journal frequencies, and explore publication years with ease. Seamlessly navigate the dynamic landscape of drug development. With daily updates, our pipeline ensures real-time data availability for your critical research. Immerse yourself in the power of our robust and up-to-date dashboard.

Back to Portal

#### Search Panel

Codename:

Upload a list of PubMed IDs

**Examples of codename** 

Choose File no file selected

Database Statistics


See more Information

submit


Difficulty finding the codename?



# Codename Pipeline – Codename Dashboard




J.M.Chem.



Properties

# Codename Pipeline – Codename Dashboard

Searched: AZD



### Manual curation results from 150 most recent J.Med.Chem

PMID	Title	First Author	PMID date	Codename	Lead name or exclu	Synonym	InChiKey	PubChem CID	PC CN2s
37145846	X-ray Crystal Structure-Guided Discovery of N	Ren Y	05/05/2023		cpd 3a				
37145039	Rationally Engineered CYP3A4 Fluorogenic Su	He RJ	05/05/2023		substrate, no SMILES				
37141440	Discovery of Potent and Wild-Type-Sparing Fo	Dong H	04/05/2023		cpd D51		YETCUDGHQDLIRZ-UHFFFAOYSA-N	<u>163288439</u>	N
37140467	Prodrug Strategies for the Development of β-	Singh US	04/05/2023	ODE-I-BHDU-MP		cpd 38			
37134237	Design, Synthesis, Biological Evaluation, and	Skácel J	03/05/2023		cpd 45i		IMXBQYQAJSJWFZ-ONEGZZNKSA-N	<u>156316535</u>	N
37134203	Design, Synthesis, and Evaluation of (R)-8-((T	Li Q	03/05/2023		cpd 10zi				N
37134182	Small Molecules Targeting DNA Polymerase T	Pismataro MC	03/05/2023		Review				
37133930	Virtual Special Issue: New Drug Modalities in	Aubé J	03/05/2023		Review				
37133411	Ψ and χ Angle Constrains at the C-Terminus T	Zhou Y	03/05/2023		Peptide 3				N
37130350	Discovery of a Potent and Oral Available Com	He P	02/05/2023	HP661					N
37130343	N-Phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol	Lane T	02/05/2023	12126065					N
37130331	Design, Synthesis, and Bioevaluation of Nove	Chen P	02/05/2023		cpd c17		LDKDGYNCHLGOIP-UHFFFAOYSA-N	<u>167440207</u>	N
37130057	Fragtory: Pharmacophore-Focused Design, Sy	Bührmann M	02/05/2023		Library deisgn				
37130037	Transformation of a Dopamine D(2) Receptor	Liu R	02/05/2023		cpd 29c				
37129317	Discovery of Potent Tetrazole Free Fatty Acid	Valentini A	02/05/2023	TUG-2304		cpd 16l			N
37116172	Thiophene Carboxamide Analogs with Long A	Ohta K	28/04/2023		cpd 2k				

			1	'			
SMILEs if no PubCher	Target HGNC	arget UniPro	Disease indication	Disease Ontology	Mechanism		Activity
COC1=C(OC)C(OC)=CC(C2=N	NC=CC3=C2N=C(C4=C	C=CC5=C4C=CN5	cancer	DOID 162	tubilin bindig		MCF-7 cells IC50 = 6nM
	EGFR	P00533	cancer	DOID 164	inhibition		IC50 = 14 nM (vs mutatant)
Br/C=C/C1=CN([C@H]2O[C(	@@H](COP(O)(OCC	OCCCCCCCCCC	Varicella zoster virus (VZV)	DOID 8536	DNA synthesis inhib	ition	
	PNP	P00491	autoimmune	DOID 417	inhibition		1C50 = 52 nM
O=C1N(C[C@@H]2OCCC2)C	TNK2	Q07912	NSCLC (lung cancer)	DOID 0080521	inhibition		IC50 = 2.1 nM
O=C1N([H])CC(N2)=C(C[C@	MC4R	P32245	cardiovascular	DOID 1287	agonist		EC50 = 4.1 nM
O=C(N1CCN(CC2=CC=C(OCC	C(F)(F)F)C=C2)CC1)C	3=C(C)N(CC4=CN:	cancer	DOID 164		Main Afiliation	
N#C/C=C/c1ccc2c(S(=O)(=O)	)n3nc(Nc4ccc(C#N)c(	P04585	HIV-associated neurocognitive disorders		antiviral RT inhibito	Southern Medica	l University, Guangzhou
	MYD88	Q99836	Acute Lung Injury - inflamation	SYMP 0000061	downregulating cyto		
			5 7 7			China Pharmaceu	itical University, Chongqing
COC1=CC=CC2=C1OC3=C2C0	DRD2	P14416	antipsychotic	DOID 2468	partial agonist	University of Geo	orgia
					<u> </u>	Czech Academy o	of Sciences
O=C(N[C@H](CC1=NN=NN1		<u>015552</u>	metabolic and inflammatory diseases	DOID 0060158	antagonist	Jinan University	·
O=C(C1=CSC=C1)NCCCCCCC	CCCCCOCCOCCOCCC	DCCCCCCCCC	cancer	DOID 164	inhibitory for gliobl		

DOID 164


EC50 = 4.1 nM		
n	Likely first patent	Notes
University, Guangzhou		likely colchecine binding site
tical University, Chongqing	CN114380806	Osimertinib resistance mutant specific L858R/T790M/C797S
rgia		
f Sciences	WO2021083438	Series of inhbitors also active against
		Analogue of ASK120067 and osimertinib
ona		Similar to Melanotan II CID92432
l University		Targeting OXPHOS complex I, related to IACS-010759 CID86711931
armaceuticals		Target is within polyprotein, long code has specifity problems
l University	CN115710251	SPR analysis of MyD88 binding affects TLR4 interaction
iversity		
enhagen		While series given TUG-codes
tical University		inhibiting mitochondri synergisitcally with temozolomide (TMZ)
·		Outside ROF but good oral bioavailability
i	University, Guangzhou  tical University, Chongqing rgia f Sciences  ona University armaceuticals University versity enhagen	Likely first patent  University, Guangzhou  dical University, Chongqing Gia Gia Gia Gia University Gia CN114380806 WO2021083438  CN1014380806 CN114380806  CN114380806

relapsed or refractory malignancies

Q07820

CIC1=CC=C2[C@@](CCCC2=


## J.Med.Chem. manual curation -150: top-level stats



#### Most recent CN from J.Med.Chem

- From 33 curated CNs with a structure
- 14 had synonym match in PubChem (i.e. CN2s)
- 2 were in ChEMBL
- 2 in BindingDB
- 4 in Guide to Pharmacology
- Thus our codename curation from J.Med.Chem. gives MDC ~50% preview

BGB-8035 CCT374705 HUM-218JG-2016 SLB1122168LUZ5 HP661SZM-1209 V2043 JSD26MYF-03-176RG7907 m-Se3ODE-I-BHDU-MPCXJ-2 NXP800R)-YNT-3708 IPG7336 TUG-230418F]NT160 LL-K8-22 SYNTiACT-777991 RK-701 OY-101\_ARN24928ZZ151 OY-101\_ARN24928ZZ151 CPD-1224 BAY-6096



## FAIR solution to the locant problem (Guide to Pharmacology > PubChem)

#### Ligand: compound 21 [Zhang et al., 2021]

Comments: Compound 21 is one of two potential lead SARS-CoV-2 antivirals from the same Bioactivity comments: Compound 21 inhibits SARS-CoV-2 replication with an EC50 of ~1 muM . In the same

#### Ligand: compound 21 [PMID: 23981033]

Comments: Compound 21 is reported as a Spirolactam-based lead compound inhibitor of acetyl-CoA carboxylase (ACC), inhibiting

#### Ligand: compound 21 [PMID: 24900635]

Comments: Compound 21 is a derivative synthesised and assessed in a medicinal chemistry study to identify
Immuno Ligand Comments: Compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in diseases associated with necroptosis (programmed in the compound 21 is a RIPK1 inhibitor with potential in the compound 21 is a RIPK1 inhibitor with potential in the compound 21 is a RIPK1 inhibitor with potential in the compound 21 is a RIPK1 inhibitor with potential in the compound 21 is a RIPK1 inhibitor with potential in the compound 21 is a RIPK1 inhibitor with potential inhibitor wi

#### Ligand: compound 21 [PMID: 22802221]

Comments: Compound 21 is a first-in-class orally administered angiotensin AT2 receptor agonist. It prevents
Immuno Ligand Comments: Compound 21 is an adenosine AT2 receptor agonist that exhibits vascular anti-inflammatory effects in vi

#### Ligand: compound 21 [PMID: 34855405]

Comments: Compound 21 is a small molecule apelin receptor agonist.

Bioactivity comments: Compound 21 induces efficacy in a rodent heart failure model, in keeping with its molecular

#### Ligand: compound 21 [PMID: 23312943]

Comments: Compound 21 is a potent inhibitor of TYRO3 protein tyrosine kinase (Sky kinase). It is suitable Bioactivity comments: compound 21, with an IC50 approximately 25 times less effective as compared to Sky inhibition

#### Ligand: compound 21 [PMID: 34141085]

Comments: Compound 21 is an orally bioavailable tankyrase inhibitor that was designed for antitumour potential. It is active

## CN2s curation: FAIR challenges

- Most Med Chem Journals are entombed in PDFs behind paywalls
- For JMC only ~ 12% of papers have CNs, with most specified by locants (e.g., 12 b)
- JMC supplementary .csv SMILES files high value however
  - short on metadata
  - difficult to machine-read
  - may not include the CN from the text
  - activity result units and error (+/-) ranges get mangled in formatting
  - challenging to parse from Figshare
- Mapping CN2s is more difficult for other Med Chem Journals
- Need OPSIN for IUPAC > structure and DECIMER for image > structure
- Markush R-group nesting makes SAR extraction difficult
- Precision of both protein target naming and diseases mapping can be variable (same old story....)

## Concluding remarks and plans

- MDC Codename project is feeding the latest curated J Med Chem CN2s to MDC Informatics, Discovery Scientists and project partners where appropriate
- Manual curation includes targets, bioactivity, disease, affiliation, PubChem CIDs, novel SMILES, molecular mechanism of action and patent mappings
- We intend to make the results open > subsumed into other public databases
- We are adapting our CN automated extraction to:
  - Apply to all recent PubMed abstracts
  - Extend portfolio mapping
  - Mine clinicaltrials.gov via disease selects
  - Intersect PubMed with PubChem searches
- Planning to investigate automated relationship extraction and contextual AI/NLP recognition of CN and compound numbers

## Acknowledgments

#### MDC colleagues:

Christopher Southan ORCID 0000-0001-9580-0446 Miguel Amaral ORCID 0000-0002-8836-2617 lan Dunlop ORCID 0000-0001-7066-3350

#### **External:**

- Prof Michael Gilson (PI of BindingDB) for instigation of author-specified SMILES as J.Med.Chem supplementary data
- Open resources for CN2s curation feeds

